Butler Hospital
Providence, Rhode Island, 02906, United States
NCT Number: NCT05206435
Participants in this randomized clinical trial will be methadone-maintained smokers interested in switching to electronic cigarettes (ECs). There will be a total of 7 study visits over the course of 6 weeks; each visit includes psychometric assessment and biomarker measurements. After completion of the baseline visit, participants will be randomized to either: 1) 6 weeks of EC use (JUUL 5% nicotine pods) or 2) 6 weeks of nicotine replacement therapy (NRT) in the form of nicotine lozenges. EC and NRT use will begin the day after the baseline assessment.
Looking for future studies?
Notify Me21 year–65 year
All sexes
Interventional
Phase 4
Providence, Rhode Island, 02906, United States
Participants in this randomized clinical trial will be methadone-maintained smokers interested in switching to electronic cigarettes (ECs). There will be a total of 7 study visits over the course of 6 weeks: baseline, 5 weekly check-in (CI) visits, and a 6-week assessment. Baseline assessments will include biomarker measurement, carbon monoxide (CO) readings, smoking history and current cigarette use, spirometry, respiratory symptoms, and tobacco demand. After completion of the baseline visit, participants will be randomized to either: 1) 6 weeks of EC use (JUUL 5% nicotine pods) or 2) 6 weeks of nicotine replacement therapy (NRT) in the form of nicotine lozenges. EC and NRT use will begin the day after the baseline assessment.
All participants will attend weekly brief assessment check-in visits where distribution of either EC or NRT will occur. Check-in assessments will include cigarette use, EC use, NRT use, CO readings, respiratory symptoms, and tobacco demand. At the 6-week assessment, baseline measurements will be repeated to determine changes in the health effects, biomarkers, and combustible cigarette use associated with 6 weeks of EC use, relative to NRT.
This study will be the first to test the potential behavioral and health effects of ECs in smokers with opioid use disorder, a population that is highly dependent on nicotine, highly vulnerable to smoking-related morbidity and mortality, and searching for novel methods to lower smoking-related risks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Electronic Cigarettes are provided to replace tobacco cigarettes
Nicotine Lozenges are provided to replace tobacco cigarettes
Time frame: 6 weeks
urinary measure of NNAL
Time frame: 6 weeks
Urinary measure of NNN
Time frame: 6 weeks
Urinary measure of 3-HPMA
Time frame: 6 weeks
Mean number of cigarettes per day assessed via the Timeline Followback over the last 6 weeks
Butler Hospital
Other
Acronym: SHINE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06472869
Behavior, Chemically-Induced Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT04709471
Behavior, Chemically-Induced Disorders
Burlington, Vermont, United States
View Trial DetailsNCT01867411
Behavior, Chemically-Induced Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT05658471
Behavior, Cardiovascular Risk Factors
San Francisco, California, United States
View Trial Details